Italian in-vitro diagnostics maker of immunodiagnostic and molecular test kits and analyzers for infectious disease and other conditions.
Italian in-vitro diagnostics maker of immunodiagnostic and molecular test kits and analyzers for infectious disease and other conditions.
Places analyzers in laboratories, often on loan or lease, and earns from the test kits the analyzers consume, so each installed machine produces repeat revenue; the more tests offered on one analyzer, the more reason a lab has to stay. The 2021 purchase of Luminex added a molecular-testing platform.
In one line: A mid-cap diagnostics maker like Quidel Ortho.
Moat: narrow (installed base, switching costs, IP / patents). Closed-system analyzers lock customers into DiaSorin's proprietary reagents once installed.
Headquarters: Saluggia, Italy · Founded: 1968 · Employees: 3,272
Size DiaSorin (DIA.MI) is an Italy Health Care company (Medical Specialties) with a market value of $4.81B, the 45th largest of 121 Italy companies the cockpit tracks. Shares closed at €81.22 on 18 Nov 2026.
Performance Over six months the shares gained 23.9%, against +22.8% for the median peer and +3.1% for the Italy market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 3.1% over the last twelve months (peer median +8.1%); the operating margin is 23.6% (peer median 13.6%).
Valuation It trades at 20.5× forward earnings against a peer median of 20.0× (9th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.7 points above its cost of capital (6.2% WACC).
Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.18B | €1.20B | €1.19B | €1.15B | €1.36B |
| Revenue growth | — | +1% | +3% | -16% | — |
| Gross profit | €683M | €700M | €708M | €669M | €827M |
| EBITDA | €405M | €433M | €407M | €351M | €502M |
| Net income | €141M | €156M | €188M | €160M | €241M |
| Free cash flow | €238M | €281M | €307M | €266M | €336M |
| Capital expenditure | €130M | €138M | €120M | €113M | €114M |
| Total debt | n/a | €791M | €1.01B | €1.19B | €1.35B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| DiaSorin DIA.MI | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
| Siemens Healthineers SHL.DE | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% |
| bioMerieux BIM.PA | $11.8B | +26% | -3% | 15% | 20.2× | 8.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DIA.MI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.2% | +5.5% | 9th lowest of 21 |
| 6-month return | +23.9% | +22.8% | 10th highest of 21 |
| Distance from 52-week high | -5.4% | -18.0% | 4th highest of 21 |
| Revenue growth (TTM) | -3.1% | +8.1% | 5th lowest of 21 |
| Operating margin | 23.6% | 13.6% | 3rd highest of 20 |
| Forward P/E | 20.5× | 20.0× | 9th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 4.1% | 10.9% | 5th least demanding of 18 |
| Growth delivered (Del g) | +6.3% | +8.2% | 6th lowest of 18 |
| Hurdle (Req g minus delivered) | -2.2 pp | +1.6 pp | 5th least demanding of 18 |
| ROIC minus cost of capital | +2.7 pp | +1.1 pp | 8th highest of 20 |
| EV / EBITDA | 12.9× | 13.8× | 7th cheapest of 14 |
| Net debt / EBITDA | 2.1× | 0.9× | 5th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DiaSorin DIA.MI | Italy | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% | +6.3% |
| Intco Medical Technology 300677.SZ | China | $4.82B | -2% | +33% | 20% | 18.5× | -3.5% | -6.4% |
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |
| Sotera Health SHC | United States | $4.65B | +5% | +7% | 37% | 15.7× | 14.4% | +7.3% |
| GRAIL GRAL | United States | $4.59B | +67% | +17% | -332% | n/a | n/a | n/a |
| Merit Medical Systems MMSI | United States | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% | +9.5% |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |